Perrigo Company plc
In the published model solve dated 2026-Q2, anchored at $13.27, Perrigo Company plc (PRGO) is priced for +12.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
- Perrigo is the leading maker of store-brand and OTC self-care products, spanning respiratory, digestive, skin, pain, and nutrition across U.S. and international segments. Trailing margins are distorted by impairments, but the through-the-cycle margin is in the low single digits. - Capital allocation is now defensive and debt-focused. The company sold its Dermacosmetics business for €305.6 million to pay down a $3.6 billion debt load, while a roughly 11% dividend yield signals the market doubts
Is PRGO overvalued? See what's priced in →
317 institutional managers reported holding PRGO in 13F filings for the quarter ended 2026-03-31. 62 opened new positions that quarter. Held by BlackRock, Vanguard Group, T. Rowe Price, among others. On the short side, 17.6M shares were sold short as of the 2026-06-15 count, about 13% of shares outstanding (4.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PRGO's share count grew 3.8% over the past five years. It pays a dividend, and has paid one every year in our records (14 and counting), raised 13 years straight; the current rate is $1.16 a share annually. Cash returned over the past three years: $428.20M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PRGO over the trailing three years: 2023: 4 buys totaling $697k; 2024: 6 buys totaling $554k; 2025: 10 buys totaling $557k. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PRGO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | +5.8% | -21.9% |
| 2023-11-08 | +2.0% | +14.8% |
| 2024-02-28 | -17.9% | +24.6% |
| 2024-05-08 | -6.9% | -12.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PRGO's latest 8-K filings: 2026-08-05 (items 2.02, 9.01); 2026-07-06 (items 5.02); 2026-06-30 (items 5.02, 7.01, 9.01); 2026-06-08 (items 5.02, 7.01, 9.01); 2026-05-06 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.